ETH rejects the 200-day EMA as heavy long liquidations fuel volatility and turn the $2.7K zone into key resistance.
CHMP is reviewing avacopan, a drug authorized in the EU for treating adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis.